Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

BMJ. 2001 May 5;322(7294):1087-8. doi: 10.1136/bmj.322.7294.1087.

Abstract

Objectives: To identify changes since 1994 in the prevalence of resistance to anti-HIV drugs in primary HIV-1 infections in the United Kingdom.

Design: Retrospective and prospective assessment of viruses obtained from people recently infected with HIV.

Setting: Multiple centres (patients enrolled in the UK register of seroconverters) and a single large HIV clinic (active case ascertainment).

Participants: 69 patients infected with HIV between June 1994 and August 2000.

Main outcome measures: Prevalence of key mutations associated with drug resistance in the reverse transcriptase and protease genes of HIV-1, by year of infection.

Results: Between June 1994 and August 2000, 10 (14%) of 69 newly infected patients had one or more key HIV-1 mutations associated with drug resistance. The risk of being infected with drug resistant virus increased over time (adjusted relative risk per year 1.74 (95% confidence interval 0.93 to 3.27), P=0.06). The estimated prevalence of drug resistance in those infected in 2000 was 27% (12% to 48%).

Conclusions: Transmission of drug resistant HIV-1 in the United Kingdom seems to be increasing. New approaches to encourage safer sexual behaviour in all sectors of the population are urgently needed.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Microbial
  • Female
  • HIV Infections / drug therapy
  • HIV Infections / transmission*
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Male
  • Mutation
  • Prevalence
  • Prospective Studies
  • Retrospective Studies

Substances

  • Anti-HIV Agents